Clinical Trial Summary Phase 1 & II, Interventional, multi-center, randomized, single-arm, multiple ascending dose study to evaluate the safety, pharmacokinetics & pharmacodynamics in patients diagnosed with AML The purpose of this study is to determine the safety, tolerability, dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of CXD in patients... Read more

Credevo conducted a feasibility on AML (Acute Myeloid Leukemia) and we received a great response from Investigator/Sites. Study details The study was Phase 1 & Phase 2, Interventional, Multi-center, Randomised, Open label, Single-arm, Multiple ascending dose with patient criteria of Acute Myeloid Leukemia non eligible for intensive chemotherapy as first-line, second-line, or... Read more